伊普诺康品牌怎么样 申请店铺

外推网助力伊普诺康品牌出海！通过在本页面挂载伊普诺康品牌的产品链接和联系邮箱，可以提高伊普诺康产品曝光！跨境电商爆单神器，目前只要100元/年哦~

[iprnocon] is a technology enterprise integrating R & D, production, sales and medical testing services in the field of in vitro diagnosis. At the beginning of its establishment, the company established the product concept of "taking the actual needs of users as the guide". The company has established a new product project approval system and a perfect product quality control system. In order to effectively implement the company's product concept, the R & D center of the company has built a number of R & D platforms, including the R & D platform of conventional biochemical reagents, the R & D platform of immune enhancement turbidimetric reagents, the R & D platform of specific protein analyzer and its reagents, and the R & D platform of urine biochemical reagents, relying on R & D talents; established a system reference department for traceability research, and signed up to participate in the rela test held by IFCC Try to improve the product quality and traceability; set up the key raw material R & D center to control the quality from the source. The company has nearly 100 registered biochemical reagent products, covering liver function, kidney function, cardiac muscle marker, blood lipid, sugar metabolism, special protein, tumor and other categories, including more than 20 featured items, such as small and dense low-density lipoprotein cholesterol (sdldl-c), complement C1q, serum amyloid A (SAA), 25 hydroxyvitamin D (25-OHD), adiponectin (ADP), and specific growth Factor (TSGF), glycocholic acid (CG), collagen IV (coliv), etc. in addition, there are dozens of registered products. The company's self-developed specific protein analyzer (dreamt200plus) will be launched in 2019, which can effectively meet the personalized needs of hospitals at all levels. The successful launch of this product marks that iprnocon has developed from a simple reagent manufacturer to a comprehensive manufacturer of reagents and instruments. "If you go far, you will be inferior to yourself, and you will pursue endlessly.". In February 2016, the company completed the listing of the "new third board" (Stock Code: 835852), and established strategic cooperation relations with a number of investment institutions, which continuously injected new impetus into the development of the company.

本文链接： https://brand.waitui.com/39e768d86.html 联系电话：请联系客服添加